U.S. Lags Behind Global Standards in Using MRI Before Prostate Biopsies

Despite guidelines and strong evidence, only about a third of American men receive a pre-biopsy MRI for prostate cancer, far fewer than patients in Europe, Canada, Australia and the U.K.

Prostate cancer accounts for over 333,000 new cases annually in the United States, but most tumors are low-grade and unlikely to be lethal. The traditional diagnostic route—PSA testing followed by systematic biopsy—detects many clinically insignificant cancers, prompting treatment in a large share of men. Internationally, a pre-biopsy MRI has become routine, reducing unnecessary biopsies by 30-50 percent and improving detection of clinically significant disease.

Although U.S. guidelines have endorsed MRI since 2020, only roughly one-third of cases used it in 2022, hindered by a learning curve for physicians, inconsistent scan quality, and the revenue that biopsies generate. Experts like Scott Eggener, Mark Emberton, Gilbert Welch, Tyler Seibert, and Michael Ahdoot highlight both the medical and economic forces sustaining the status quo, while calling for broader adoption of MRI-guided pathways. Research continues to evaluate whether eliminating systematic biopsies altogether can maintain cancer control while sparing patients from overtreatment.